KR102286075B1 - Staphylococcus lentus ST-2 strain and skin condition improving uses of thereof - Google Patents

Abstract

It relates to a novel microorganism, its lysate, a culture solution, an extract of the culture solution, and their use for improving skin condition.

Description

Staphylococcus lentus ST-2 strain and use of improving skin condition thereof {Staphylococcus lentus ST-2 strain and skin condition improving uses of thereof}

It relates to a novel microorganism, its lysate, a culture solution, an extract of the culture solution, and their use for improving skin condition.

The skin ecosystem provides various types of habitat for microorganisms, and a wide range of microorganisms live there. Human beings, the host, form a symbiotic relationship with them and are known to have many positive effects on the host. The skin constitutes various types of habitats, such as depressions and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical barrier and helps to defend against potential hazards and toxic substances from the outside. The skin becomes a connection point with the external environment and is also a gathering place for various microorganisms (fungi, bacteria, viruses and small larvae). In accordance with the selection of physical and chemical functions, microorganisms adapt to specialized niches and prepare habitats. In general, the skin is cold, acidic, and remains dry. Structurally, the epidermis forms the skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in maintaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum. The epidermis has a so-called 'brick and mortar structure', and the skin tissue undergoes a continuous self-healing process, and the scales (squames) that have undergone the final differentiation process repeat the process of being continuously removed from the skin tissue.

Probiotics are microorganisms that have beneficial effects on the human body. Most probiotics known to date are known as lactic acid bacteria. Probiotics have been reported to produce effective efficacy through various beneficial effects on the human body, but studies on the interaction between skin flora and skin are scarce.

Accordingly, there is a need for the development of skin flora that can be usefully used for skin-related conditions.

One aspect is to provide a Staphylococcus lentus ST-2 (Staphylococcus lentus ST-2) strain belonging to the genus Staphylococcus sp.

Another aspect is to provide a lysate of the strain, a culture solution, or an extract of the culture solution.

Another aspect is to provide a composition comprising the strain, a lysate thereof, a culture solution, and an extract of the culture solution.

One aspect provides a Staphylococcus lentus ST-2 strain.

The Staphylococcus lentus ST-2 strain may be a strain deposited with accession number KCCM12547P.

The Staphylococcus lentus ST-2 strain may be a strain comprising 16s rRNA of SEQ ID NO: 1.

The strain may have a skin beauty improvement effect, for example, skin aging inhibition, skin whitening, skin barrier strengthening, skin wrinkle inhibition, or skin moisturizing effect.

The strain may increase the expression of hyaluronic acid synthase 3 (HAS3: Hyaluronan synthase 3), or filaggrin.

Another aspect provides a lysate of the strain, a culture solution, or an extract of the culture solution.

The strain is as described above.

As used herein, the term "culture medium" may be used interchangeably with "culture supernatant", "conditioned culture medium" or "conditioned medium", and allows the Staphylococcus lentus ST-2 strain to grow and survive in vitro. It may mean the entire medium including the strain obtained by culturing the strain for a certain period of time in a medium capable of supplying nutrients, its metabolites, and extra nutrients. In addition, the culture solution may refer to a culture solution obtained by culturing the strain in which the cells are removed from the culture solution. On the other hand, the liquid from which the cells have been removed from the 　 culture solution 　 is also called a “supernatant”, and the 　 culture solution is left for a certain period of time to take only the liquid from the upper layer except for the part that has sunk to the lower layer, remove the cells through filtration, or 　 centrifuge the culture solution to the lower part It can be obtained by removing the precipitation of and taking only the liquid at the top. The "cell" of the present invention refers to the strain itself of the present invention, and includes the strain isolated and selected from a skin sample, or the strain isolated from the culture solution by culturing the strain. The cells can be obtained by centrifuging the 　 culture solution to take the part that has sunk to the lower layer, or by removing the liquid from the upper layer after leaving it still for a certain period of time because it sinks into the lower layer of the culturing solution by gravity.

The culture medium may include the culture medium itself obtained by culturing the strain, its concentrate, or a lyophilisate or a culture supernatant obtained by removing the strain from the culture medium, its concentrate or lyophilisate.

The culture medium is a Staphylococcus lentus ST-2 strain in a medium (eg, R2A medium or TSA medium) at any temperature of more than 10 ° C or less than 40 ° C for a certain period of time, for example, culturing for 4 to 50 hours. It may be obtained by

In one embodiment, the culture supernatant of the strain may be obtained by centrifuging or filtering the strain culture to remove the strain.

In another embodiment, the concentrate may be obtained by concentrating the supernatant obtained after filtering the strain culture solution itself, or the culture solution using centrifugation or a filter.

The culture medium and culture conditions for culturing the Staphylococcus lentus ST-2 strain may be appropriately selected or modified by those of ordinary skill in the art.

As used herein, the term “lysate” may refer to a product obtained by disrupting the cell wall of the strain itself by chemical or physical force.

As used herein, the term "culture solution extract" means extraction from the culture solution or its concentrate, and may include an extract, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or these prepared or purified products, and a fraction obtained by fractionating it. can

Another aspect provides the use of the strain, a lysate of the strain, a culture solution, or an extract of the culture solution. Specifically, it provides a composition comprising a Staphylococcus lentus ST-2 strain, a lysate thereof, a culture medium, or an extract of the culture medium.

The use of the strain may include improving skin condition, improving skin beauty, preventing, improving or treating skin diseases, preventing, improving, or treating skin inflammatory diseases.

The skin condition improvement or skin beauty improvement may be skin aging inhibition or improvement, anti-wrinkle, skin whitening, skin barrier strengthening, or skin moisturizing.

As used herein, the term "skin aging" refers to the tangible and intangible changes that appear on the skin with age, for example, a phenomenon in which the thickness of the epidermis becomes thin, the number of cells or blood vessels in the dermis, DNA damage repair ability, cell replacement cycle, It refers to a decrease in wound healing, skin barrier function, epidermal moisture retention, sweat secretion, sebum secretion, vitamin D production, physical damage defense, chemical removal ability, immune response, sensory function, and thermoregulation.

The strain or its culture medium may be for improving skin aging caused by extrinsic factors or intrinsic factors. The extrinsic factor refers to various external factors, such as ultraviolet rays (light), and the intrinsic factor is also referred to as a chronological factor and refers to a factor mainly caused by the passage of time. That is, the skin aging specifically refers to not only the premature aging symptoms induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, chemical substances, etc., but also a natural aging phenomenon that occurs as the proliferation of skin cells decreases with aging. It is a concept that includes all of wrinkles, loss of elasticity, sagging skin, and dryness. In addition, wrinkles include those that cause wrinkles by changing the components constituting the skin tissue by stimulation by changes in internal and external factors.

The aging may be photoaging. The term “photoaging” is a phenomenon induced by external environmental factors, and the most representative factor is ultraviolet rays. Ultraviolet rays cause damage to biological components such as activation of proteolytic enzymes, chain cleavage of matrix proteins, and abnormal cross-linking, and repetition of these mechanisms leads to apparent skin aging.

As used herein, the term “wrinkle” refers to a state in which the elasticity of the skin is lost and loosened, and for example, the skin may be folded. Pigmentation refers to a condition in which the amount of pigment in the body is abnormal or there is an abnormality in the place where the pigment appears, and may be, for example, spots and freckles. The "prevention or improvement of skin wrinkles" may refer to any action of preventing or improving wrinkles by inhibiting the expression of factors related to wrinkles, or increasing the total amount of collagen.

The "skin whitening" may mean not only to brighten skin tone by inhibiting the synthesis of melanin pigment, but also to improve skin hyperpigmentation such as spots or freckles caused by ultraviolet rays, hormones, or heredity.

The "skin barrier strengthening" may refer to any action of enhancing the function of the skin barrier that is located at the outermost part of the skin and prevents loss of moisture and nutrients.

The "skin moisturizing" may refer to any action that maintains skin moisture or prevents moisture loss.

The term, “anti-inflammatory” may be used interchangeably with “inhibiting or improving inflammation”, and may refer to any action in which an immune response is alleviated to suppress NO production.

The "skin disease" may be a disease caused by damage to the skin barrier function, skin aging, skin wounds, skin scars, or skin inflammation. The term “prevention” includes inhibiting the development of a disease. The term "treatment" includes inhibiting, alleviating, or eliminating the development of a disease.

The damage to the skin barrier function may refer to any change that appears in the skin as the function of the skin barrier is reduced or damaged. For example, it may include increased skin wrinkles, dryness, dermatitis, atopic dermatitis, allergic dermatitis, acne, and the like.

The skin inflammatory disease may be any one selected from the group consisting of skin wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, weak rash, and acne.

In another embodiment, the strain may be used together with a strain belonging to the genus Staphylococcus, which is another strain having a skin improvement effect, to show a synergistic effect. Examples of strains belonging to the genus Staphylococcus include S. argenteus , S. aureus , S. schweitzeri , S. simiae , S. auricularis , S. carnosus , S. condimenti , S. debuckii , S. massiliensis , S. piscifermentans , S. simulans, S. capitis , S. caprae , S. epidermidis , S. saccharolyticus, S. devriesei , S. haemolyticus , S. hominis, S. hyicus-intermedius , S. agnetis , S. chromogenes , S. cornubiensis S. felis , S. delphini , S. hyicus , S. intermedius , S. lutrae , S. microti , S. muscae , S. pseudintermedius , S. rostri , S. schleiferi , S. lugdunensis , S. arlettae , S. caeli , S. cohnii , S. equorum , S. gallinarum , S. kloosii , S. leei , S. nepalensis , S. saprophyticus , S. succinus , S. xylosus , S. fleurettii , S. lentus , S. s S. stepanovicii , S. vitulinus , S. simulans , S. pasteuri , or S. warneri . More specifically, examples of strains belonging to the genus Staphylococcus include Staphylococcus capitis ST-1, Staphylococcus lentus ST-2, Staphylococcus lentus ST-2, and Staphylococcus conii. ST-3 ( Staphylococcus cohnii ST-3), Staphylococcus gallinarum ST-4 ( Staphylococcus gallinarum ST-4), Staphylococcus saprophyticus ST-5 ( Staphylococcus saprophyticus ST-5), Staphylococcus epi Staphylococcus epidermidis ST-6, Staphylococcus sciuri ST-7, Staphylococcus haemolyticus ST-8, Staphylococcus simulation Lance ST-9 ( Staphylococcus simulans ST-9), Staphylococcus xylosus ST-10 ( Staphylococcus xylosus ST-10), Staphylococcus intermedius ST-11 ( Staphylococcus intermedius ST-11), Staphylococcus Reneri ST-12 ( Staphylococcus warneri ST-12), or Staphylococcus schleiferi ST-13 (Staphylococcus schleiferi ST-13).

The composition comprises 0.001 wt% to 80 wt%, for example, 0.01 wt% to 60 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt%, 0.01 wt% to 20 wt%, based on the total weight of the composition %, 0.01% to 10%, 0.01% to 5%, 0.05% to 60%, 0.05% to 40%, 0.05% to 30%, 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% by weight % to 10% by weight, or 0.1% to 5% by weight of a strain, a lysate thereof, a culture solution, or an extract of a culture solution thereof.

The term, "included as an active ingredient" means that the extract of the strain of the present specification, its lysate, culture, or its culture is added to the extent that it can exhibit the above-mentioned effects, and various for drug delivery and stabilization, etc. It is meant to include being formulated in various forms by adding the component as a sub-component.

The composition may be a cosmetic composition.

The cosmetic composition may have a cosmetic formulation of, for example, a softening lotion, a nourishing lotion, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule, or a skin adhesion type.

Components included in the cosmetic composition may include components commonly used in cosmetic compositions in addition to the composition as an active ingredient, for example, conventional adjuvants and carriers such as stabilizers, solubilizers, vitamins, pigments and fragrances. may include.

In addition, the composition may be a composition for external application to the skin.

In the present specification, the external preparation for skin may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The external preparation for skin is a component normally used in external preparations for skin such as cosmetics or pharmaceuticals, for example, an aqueous component, an oily component, a powder component, alcohol, a moisturizer, a thickener, an ultraviolet absorber, a whitening agent, a preservative, an antioxidant, a surfactant, a fragrance , colorant, various skin nutrients, or a combination thereof may be appropriately formulated as needed. The external preparation for skin includes metal sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, belapamil, licorice extract, glablidine, and kaline. Fruit hot water extract, various herbal medicines, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, Sugars, such as trehalose, etc. can be mix|blended suitably.

In another embodiment, the composition may be a pharmaceutical composition.

The pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be carboxymethyl cellulose calcium, sodium starch glycolate, anhydrous calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrups, or a combination thereof. The parenteral dosage form may be an injection.

The composition may be a health functional food composition.

The health functional food composition may be used alone or in combination with other foods or food ingredients of the strain or its culture, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prophylactic, health or therapeutic treatment). In general, in the production of food or beverage, the composition of the present specification may be added in an amount of 15 parts by weight or less based on the raw material. There is no particular limitation on the type of the health functional food. Among the types of health functional food, the beverage composition may contain various flavoring agents or natural carbohydrates as additional components, like a conventional beverage. The natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used. The health food composition may also be added to nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonated beverages the carbonation agent used, or a combination thereof. The health functional food composition may also contain natural fruit juice, fruit juice beverage, fruit flesh for the production of vegetable beverage, or a combination thereof.

Another aspect also provides a method of preventing, ameliorating, or treating a condition in a subject comprising treating or administering to the subject in need thereof an effective amount of the composition described above.

The subject's condition may be a condition related to skin or a condition related to inflammation.

The terms “administering”, “introducing”, and “implanting” are used interchangeably and in one embodiment into a subject by a method or route that results in at least partial localization of the composition according to one embodiment to a desired site. It may refer to the arrangement of the composition according to the example.

Administration may be administered by methods known in the art. Administration can be administered directly to a subject by any means, for example, by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. can The administration may be systemically or locally.

The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be an individual in need of skin beauty improvement, for example, skin moisturizing, skin barrier strengthening, skin inflammation suppression, and skin wrinkle improvement effect.

The administration is 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1 mg of the composition according to one embodiment per day 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg may be administered. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and response sensitivity, and those skilled in the art The dosage may be appropriately adjusted in consideration of these factors. The number of administration may be once a day or twice or more within the range of clinically acceptable side effects, and may be administered to one or two or more sites for the administration site, and total daily or at intervals of 2 to 5 days. The number of days of administration may range from 1 to 30 days per treatment. If necessary, the same treatment can be repeated after a titration period. For animals other than humans, the same dose as that of humans per kg or, for example, the above dose is converted by the volume ratio (for example, average value) of an organ (heart, etc.) between the target animal and human. One dose can be administered.

According to the novel Staphylococcus lentus ST-2 strain in one aspect, there is an effect that can be usefully used for preventing, improving, or treating skin-related conditions or inflammation-related conditions.

1 is a graph showing the effect of a strain according to an embodiment on the expression of COL1A1.
2 is a graph showing the effect of a strain according to an embodiment on the expression of MMP-1.
3 is a graph showing the effect of the strain according to one embodiment on the expression of HAS3.
4 is a graph showing the effect of a strain according to an embodiment on the expression of filaggrin.
5 is a graph showing the effect of the strain according to one embodiment on the inflammatory cytokine IL-6.
6 is a graph showing the effect of a strain according to an embodiment on inflammatory cytokines.

Hereinafter, it will be described in more detail through examples. However, these examples are for illustrative purposes of one or more embodiments, and the scope of the present invention is not limited to these examples.

Example. Isolation and identification of strains

A sample (human epidermal keratinocyte) obtained by washing the skin of a healthy woman with sterile distilled water was inoculated into R2A medium (Becton Dickinson, Cockeysville, MD). After inoculation, 100 colonies formed after culturing in a 28 ℃ incubator for 48 hours after inoculation were purely separated and cultured, and cultured in a 28 ℃ incubator for 48 hours. The cultured colonies were subjected to 16s rRNA gene sequence identification. The primers used in this case were designed to amplify in response only to bacteria (SEQ ID NOs: 2 and 3). PCR amplification was carried out in 30 cycles of 95°C for 1 minute, 55°C for 1 minute, and 75°C for 1 minute and 30 seconds, and finally, after treatment at 72°C for 8 minutes, it was stored at 4°C. After the PCR reaction, the DNA sequences of the isolated and cultured species were determined using ABI-3730XL (ABI, USA). When the nucleotide sequence of the 16S rRNA region determined from the isolated and cultured microbial colonies is compared with other strains registered with the BLAST program provided on the website of the National Center for Biotechnology Information (NCBI), homology is 98% or less Only novel species of were selected and used, and among them, a novel microorganism Staphylococcus lentus ST-2 with less than 98% homology (hereinafter referred to as "ST-2") was selected. The selected ST-2 strain was deposited with the Korea Microbial Conservation Center on June 11, 2019 and was given an accession number KCCM12547P, and the ST-2 strain has a 16s rRNA sequence of SEQ ID NO: 1 (complementary DNA).

experimental example. strain activity

In this experimental example, the activity of the identified strain was confirmed, and as a control strain, KCCM 41469 Staphylococcus lentus strain (obtained from the Korea Microbial Conservation Center) (hereinafter referred to as "Type Strain") was used.

Anti-aging and anti-wrinkle activity assay

The effect of the culture medium of the strain on factors related to aging skin aging and wrinkle generation by ultraviolet (UV) irradiation was analyzed.

Specifically, a human dermal fibroblast (Hs68) cell line ^{was aliquoted in a 6-well plate at a volume of 3.5x10 5} , and then cultured in an incubator at 37° C. and 5% CO _{2 condition for 24 hours.} After removing the medium and adding DPBS, 12 mJ/cm ² of UVB was irradiated or not irradiated. Immediately after UVB irradiation, DPBS was removed and replaced with a medium without FBS, treated with the culture solution of the ST-2 strain (1% (w/w)) and further cultured for 24 hours. As a negative control group, UV-treated and non-treated strain culture groups were used. After that, RNA was isolated from the cells of each sample using trizol (RNA iso, DAKARA, Japan), and RNA was quantified at 260 nm with nanodrops, and cDNA was synthesized in an amplifier using 2 μg of each RNA. (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, for the target genes MMP-1 (Matrix metalloproteinase-1) and COL1A1, cybergreen (SYBR Green supermix, Applied Biosystems, USA) was added together with a primer and cDNA to a real-time PCR machine Real-time polymerase chain reaction was performed in (Step One Plus, Applied Biosystems, USA). The expression level of the gene was finally analyzed through correction for the β-actin gene, and the results are shown in FIGS. 1 and 2 .

As shown in FIG. 1 , it was found that the strain according to one embodiment significantly increased the expression of COL1A1 reduced by ultraviolet light.

As shown in Figure 2, it was found that the strain according to one embodiment significantly reduced the expression of MMP-1 increased by ultraviolet irradiation.

These results mean that the ST-2 strain according to one embodiment has an effect to improve aging (eg, photoaging).

Skin barrier strengthening and skin moisturizing activity analysis

The effect of the culture medium of the strain on skin barrier strengthening and skin moisturizing activity was analyzed.

Specifically, HaCaT cells, a human keratinocyte cell line, were cultured in DMEM medium (Dulbecco'smodified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovin serum, all of which were cultured at 37°C, 5% CO ₂ incubator. The cultured cell line was treated with the culture solution (1% (w/w)) of the ST-2 strain and further cultured for 24 hours. The expression levels of HAS3 and filaggrin were measured in the same manner as in Experimental Example except that primers for HAS3 (hyaluronic acid synthase) and filaggrin, factors related to skin barrier strengthening and moisturizing, were used. did. The results are shown in FIGS. 3 and 4, respectively.

As shown in FIGS. 3 and 4 , it was found that the strain according to one embodiment significantly increased the expression levels of both HAS3 and filaggrin.

These results mean that the ST-2 strain according to one embodiment can be usefully used for strengthening the skin barrier and moisturizing the skin.

Anti-inflammatory activity assay

In order to analyze whether the culture of the strain has anti-inflammatory activity, the effect of the culture of the strain on the expression of IL-6 in the human fibroblast cell line was confirmed, and the results are shown in FIG. 5 .

As shown in Figure 5, the strain according to one embodiment was found to significantly reduce the expression of the pro-inflammatory cytokine IL-6 compared to the untreated control group.

In addition, HaCaT cells, a human keratinocyte, were cultured in DMEM medium (Dulbecco'smodified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovin serum, and all cultures were cultured at 37°C, 5 % CO _{2 in an} incubator. The medium was changed every 3 to 4 days, and subculture was performed when the cells were excessively proliferated. Thereafter, the cells were aliquoted at 5x10 ⁵ /well, and after 24 hours of incubation, they were washed with a phosphate buffered saline solution (PBS). Cells were aliquoted into each well containing DMEM medium without FBS, and Poly I:C 10 μg/ml, and IL-4 were added at 10 ng/ml. Next, the culture solution (1% concentration) of the strain was treated, and further cultured for 4 hours. The expression level of IL-1α was analyzed in the same manner as in Experimental Example except that a primer for IL-1α was used, and the results are shown in FIG. 6 .

As shown in FIG. 6 , it was found that the strain according to one embodiment significantly reduced the expression of IL-1α, an inflammatory cytokine, compared to the untreated control group.

These results mean that the ST-2 strain according to one embodiment can be usefully used for preventing, improving, or treating skin inflammatory diseases.

Korea Microorganism Conservation Center (Overseas) KCCM12547P 20190611

SEQUENCE LISTING <110> COSMAX, Co.Ltd <120> Staphylococcus lentus ST-2 strain and skin condition improving uses of <130> PN129371 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 1470 <212> DNA <213> Staphylococcus lentus <400> 1 aggatgaacg ctggcggcgt gcctaataca tgcaagtcga gcgaacagat gagaagcttg 60 cttctctgat gttagcggcg gacgggtgag taacacgtgg gtaacctacc tataagactg 120 ggataactcc gggaaaccgg ggctaatacc ggataatata ttgaaccgca tggttcaatg 180 ttgaaagacg gtttcggctg tcacttatag atggacccgc gccgtattag ctagttggta 240 aggtaacggc ttaccaaggc aacgatacgt agccgacctg agagggtgat cggccacact 300 ggaactgaga cacggtccag actcctacgg gaggcagcag tagggaatct tccgcaatgg 360 gcgaaagcct gacggagcaa cgccgcgtga gtgatgaagg tcttaggatc gtaaaactct 420 gttgttaggg aagaacaaat ttgttagtaa ctgaacaagt cttgacggta cctaaccaga 480 aagccacggc taactacgtg ccagcagccg cggtaatacg taggtggcaa gcgttatccg 540 gaattattgg gcgtaaagcg cgcgtaggcg gtttcttaag tctgatgtga aagcccacgg 600 ctcaaccgtg gagggtcatt ggaaactggg gaacttgagt gcagaagagg agagtggaat 660 tccatgtgta gcggtgaaat gcgcagagat atggaggaac accagtggcg aaggcggctc 720 tctggtctgt aactgacgct gatgtgcgaa agcgtgggga tcaaacagga tagataccc 780 tggtagtcca cgccgtaaac gatgagtgct aagtgttagg gggtttccgc cccttagtgc 840 tgcagctaac gcattaagca ctccgcctgg gggagtacgac cgcaaggttg aaactcaaag 900 gaattgacgg ggacccgcac aagcggtgga gcatgtggta taattcgaag caacgcgaag 960 aaccttacca aatcttgaca tcctttgatc gctctagaga tagagttatc cccttcgggg 1020 gacaaagtga caggtggtgc atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag 1080 tcccgcaacg agcgcaaccc ttaagcttag ttgccatcat taagttgggc actctaggtt 1140 gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aaatcatcat gccccttatg 1200 atttgggcta cacacgtgct acaatggata atacaaaggg cagcgaaccc gcgaggtcaa 1260 gcaaatccca taaaattatt ctcagttcgg attgtagtct gcaactcgac tacatgaagc 1320 tggaatcgct agtaatcgta gatcagcatg ctacggtgaa tacgttcccg ggtcttgtac 1380 acaccgcccg tcacaccacg agagtttgta acacccgaag ccggtggagt aaccttatat 1440 taggagctag ccgtcgaagg tgggacagat 1470 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> primer for bacteria <400> 2 agagtttgat cmtggctcag 20 <210> 3 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> primer for bacteria <400> 3 tacggytacc ttgttacgac tt 22

Claims (6)

Deposited with accession number KCCM12547P, and comprising the 16s rRNA sequence of SEQ ID NO: 1, Staphylococcus lentus ST-2 belonging to the genus Staphylococcus ( Staphylococcus lentus ST-2) strain. The culture solution of the strain of claim 1. A cosmetic composition comprising the strain of claim 1, its lysate or culture solution. The cosmetic composition according to claim 3, which is for improving skin beauty. A pharmaceutical composition for the prevention or treatment of skin inflammatory diseases comprising the strain of claim 1, its lysate or culture solution as an active ingredient. The composition of claim 5, wherein the skin inflammatory disease is any one selected from the group consisting of skin wounds, dermatitis, atopic dermatitis, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, weak rash, and acne. .

Images